Autoantibodies : detection, pathogenicity, and health implications /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Jenkins, Graham E. (Editor ), Hall, Joanne I. (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: [Hauppauge] New York : Nova Science Publishers, Incorporated, [2012]
Colección:Immunology and immune system disorders.
Public health in the 21st century series.
Temas:
Autoantibodies.
Autoantibodies > Analysis.
Autoimmunity.
Autoantibodies
Autoimmunity
Autoanticorps.
Autoanticorps > Analyse.
Auto-immunité.
MEDICAL > Immunology.
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 i 4500
001 EBSCO_on1162041497
003 OCoLC
005 20231017213018.0
006 m o d
007 cr |||||||||||
008 120312s2012 nyua ob 001 0 eng
010 |a  2020679769 
040 |a DLC  |b eng  |e rda  |e pn  |c DLC  |d VLY  |d OCLCO  |d YDXCP  |d E7B  |d N$T  |d OCLCF  |d EBLCP  |d DEBSZ  |d AGLDB  |d VTS  |d AU@  |d STF  |d K6U  |d OCLCQ  |d SNK  |d OCLCO  |d OCLCQ 
019 |a 837578466 
020 |a 9781620815885  |q (ebook) 
020 |a 1620815885 
020 |z 9781620815601  |q (hardcover) 
020 |z 1620815605  |q (hardcover) 
029 1 |a DEBBG  |b BV042795285 
029 1 |a DEBSZ  |b 456602615 
029 1 |a DEBSZ  |b 472782908 
035 |a (OCoLC)1162041497  |z (OCoLC)837578466 
042 |a pcc 
050 0 0 |a QR186.82 
072 7 |a MED  |x 044000  |2 bisacsh 
082 0 0 |a 616.07/9  |2 23 
049 |a UAMI 
245 0 0 |a Autoantibodies :  |b detection, pathogenicity, and health implications /  |c Graham E. Jenkins and Joanne I. Hall, editors. 
264 1 |a [Hauppauge] New York :  |b Nova Science Publishers, Incorporated,  |c [2012] 
300 |a 1 online resource 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Immunology and immune system disorders 
490 1 |a Public health in the 21st century 
504 |a Includes bibliographical references and index. 
588 0 |a Print version record and CIP data provided by publisher. 
546 |a English. 
505 0 |a AUTOANTIBODIES DETECTION, PATHOGENICITY AND HEALTH IMPLICATIONS ; AUTOANTIBODIES DETECTION, PATHOGENICITY AND HEALTH IMPLICATIONS ; CONTENTS ; PREFACE ; IMPLICATED AUTOANTIBODIES IN A KIDNEY DISEASE ; ABBREVIATIONS ; ADDITIONAL WELL KNOWN ABBREVIATIONS ; ABSTRACT ; INTRODUCTION ; AUTOIMMUNITY ; DETECTION OF AABS IN THE CIRCULATION AND IN SITU PATHOGENIC AAB RESPONSE AGAINST TARGET ANTIGENIC SITES IN THE KIDNEYS OF SPHN RATS ; PATHOGENICITY OF IGG AABS AGAINST KIDNEY AGS IN SPHN ; NON-PATHOGENIC IGM AABS AGAINST KIDNEY AGS IN SPHN ; HEALTH IMPLICATIONS. 
505 8 |a PREVENTION AND TREATMENT OF A PATHOGENIC IGG AAB INITIATED AND MAINTAINED EXPERIMENTAL AUTOIMMUNE DISEASE BY THE MODIFIED VACCINATION TECHNIQUE (MVT) CONCLUSION ; ACKNOWLEDGMENTS ; REFERENCES ; ANTI-FACTOR H AUTOANTIBODIES IN KIDNEY DISEASE: DETECTION, PATHOGENIC ROLE AND RELEVANCE FOR TREATMENT; ABSTRACT ; INTRODUCTION ; FACTOR H; ANTI-FACTOR H AUTOANTIBODIES; Anti-Factor H Autoantibodies in Atypical Hemolytic Uremic Syndrome ; Anti-Factor H Autoantibodies in Dense Deposit Disease ; Anti-Factor H Autoantibodies in other Diseases ; DETECTION OF ANTI-FACTOR H AUTOANTIBODIES. 
505 8 |a ARE ANTI-FACTOR H AUTOANTIBODIES PATHOGENIC? RELEVANCE OF THE AUTOANTIBODIES TO TREATMENT ; CONCLUSION ; ACKNOWLEDGMENTS ; REFERENCES ; AUTOANTIBODIES IN ALZHEIMER'S DISEASE ; ABSTRACT ; INTRODUCTION ; THE BLOOD-BRAIN-BARRIER (BBB): CONNECTION TO THE AD AUTOIMMUNITY HYPOTHESIS; AUTOANTIBODIES AGAINST AB PEPTIDES ; AUTOANTIBODIES AGAINST ATP SYNTHASE ; REDOX REACTIVE AUTOANTIBODIES ; AUTOANTIBODIES AGAINST NICOTINIC ACETYLOCHOLINE RECEPTORS ; AUTOANTIBODIES AGAINST GANGLIOSIDE GM1 ; AUTOANTIBODIES AGAINST OXIDIZED LOW-DENSITY LIPOPROTEIN. 
505 8 |a AUTOANTIBODIES AGAINST SERINE/ARGININE PROTEIN KINASE 1 AUTOANTIBODY PROFILES IN HUMAN SERA ; CONCLUSION ; ACKNOWLEDGMENTS; REFERENCES; AUTOIMMUNITY IN CARDIOVASCULAR DISEASE; ABSTRACT ; COMMON ABBREVIATIONS USED IN THIS TEXT ; 1.0. DEFINITION OF AUTOIMMUNITY ; 2.0. CLINICAL SIGNIFICANCE OF DILATED CARDIOMYOPATHY AND PREECLAMPSIA ; 2.1. Dilated Cardiomyopathy Characteristics and Prevalence ; 2.2. Preeclampsia Characteristics and Prevalence ; 3.0. DILATED CARDIOMYOPATHY AUTOANTIBODY IMPORTANCE ; 3.1. Ý1-Adrenergic Receptor Agonistic Autoantibody (Ý1R-AA) 
505 8 |a 3.2. Muscarinic M2 Receptor Agonistic Autoantibody (M2R-AA) 3.3. Clinical Significance ; 4.0. AUTOANTIBODY AND SIGNIFICANCE IN PREECLAMPSIA ; 4.1. In Vitro Studies of PE ; 4.2. Effects of PE in Various Laboratory and Clinical Settings ; A. Mouse Studies with Adoptive Transfer ; B. Rat Studies with Adoptive Transfer ; C. Human Evidence Supporting Autoantibody Role in PE ; 5.0. AUTOANTIBODY RECEPTOR BINDING AND PRODUCTION ; 5.1. Mechanisms Underlying Ý1R-AA Production ; 5.2. Mechanisms Underlying AT1-AA Production and Function; 6.0. THERAPEUTIC CONSIDERATIONS. 
590 |a eBooks on EBSCOhost  |b EBSCO eBook Subscription Academic Collection - Worldwide 
650 0 |a Autoantibodies. 
650 0 |a Autoantibodies  |x Analysis. 
650 0 |a Autoimmunity. 
650 2 |a Autoantibodies 
650 2 |a Autoimmunity 
650 6 |a Autoanticorps. 
650 6 |a Autoanticorps  |x Analyse. 
650 6 |a Auto-immunité. 
650 7 |a MEDICAL  |x Immunology.  |2 bisacsh 
650 7 |a Autoantibodies.  |2 fast  |0 (OCoLC)fst00822532 
650 7 |a Autoantibodies  |x Analysis.  |2 fast  |0 (OCoLC)fst00822533 
650 7 |a Autoimmunity.  |2 fast  |0 (OCoLC)fst00822674 
700 1 |a Jenkins, Graham E.,  |e editor. 
700 1 |a Hall, Joanne I.,  |e editor. 
776 0 8 |i Print version:  |t Autoantibodies.  |d [Hauppauge] New York : Nova Science Publishers, Inc., [2012]  |z 9781620815601  |w (DLC) 2012935164 
830 0 |a Immunology and immune system disorders. 
830 0 |a Public health in the 21st century series. 
856 4 0 |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541271  |z Texto completo 
938 |a ProQuest Ebook Central  |b EBLB  |n EBL3020980 
938 |a ebrary  |b EBRY  |n ebr10681180 
938 |a EBSCOhost  |b EBSC  |n 541271 
938 |a YBP Library Services  |b YANK  |n 9371477 
994 |a 92  |b IZTAP 

Ejemplares similares